1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Market Access Impact: Renal Cell Carcinoma (EU5) 2018

Market Access Impact: Renal Cell Carcinoma (EU5) 2018

  • April 2018
  • ID: 5438883
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Market barriers affect 14 percent of RCC prescriptions in Europe. Is your brand losing out?

Despite market barriers only affecting 14 percent of all renal cell carcinoma (RCC) prescriptions in Europe, certain brands are losing on market share. Is it yours? Find out what’s driving share gains, and what your brand can do to level the playing field in Market Access Impact: RCC (EU5) [2018]. Based on a survey of 150 medical oncologists, the report covers 10 major therapies from Novartis, Roche, Ipsen, Pfizer, Exelixis, Amgen, Bayer, and BMS. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways
• Barriers affect 14 percent of all prescriptions. Small, perhaps, but brands are still losing out on market share opportunities because of them. Is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
• Four brands see robust share increases. Is this lead too big for the chasing pack to overcome? Is your brand leading, or are you in the chasing pack?

• One brand sees a significant loss. Perhaps due to limited prescribing, but other issues could be at play. What are these issues, and what can be done about them?

• Eliminating barriers would close the gap mid-table. Due to the overall barrier impact being below 10 percent, changes at the top and bottom of the table won’t be seen if barriers are eliminated; not so mid-table, where changes would be seen.

• Perception is not the problem. But perhaps a willingness to use is? Between 17-21 percent of physicians would not consider using 3 brands? Is your brand in the mix?

Insight into 10 Major RCC Treatments
• Afinitor (everolimus; Novartis)
• Avastin (bevacizumab; Roche)
• Cabometyx (cabozantinib; Exelixis/Ipsen)
• Inlyta (axitinib; Pfizer)
• Kisplyx (lenvatinib; Eisai)
• Nexavar (sorafenib; Bayer)
• Opdivo (nivolumab; Bristol-Myers Squibb)
• Sutent (sunitinib; Pfizer)
• Torisel (temsirolimus; Pfizer)
• Votrient (pazopanib; Novartis)

Exploring Important Market Access Issues

Market Access Impact: Renal Cell Carcinoma (EU5) explores key issues affecting RCC drug manufacturers. You’ll learn:

How barriers affect market access:
• What brands do doctors prescribe the most?
• How many prescriptions do barriers affect?
• Which barriers have the biggest impact?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Angiopoietin 1 Receptor - Pipeline Review, H2 2019

Angiopoietin 1 Receptor - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Angiopoietin 1 Receptor - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Angiopoietin 1 Receptor - Pipeline Review, H2 2019’; Angiopoietin 1 Receptor (Endothelial Tyrosine ...

Kidney Cancer Treatment Drugs Markets in China

Kidney Cancer Treatment Drugs Markets in China

  • $ 4000
  • August 2019

China’s demand for Kidney Cancer Treatment Drugs has grown at a fast pace in the past decade.In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2019SummaryTumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on